As far as the market is concerned this is now a dead issue, as sad as it sounds. Teva received the best possible outcome at the trial and the stock did absolutely nothing. It not only took us by surprise but all the analysts as well. I am now convinced the only thing now which will make the stock price appreciate is a revision upwards in earnings or a brand named drug launch and I do not see any of these 2 things happening any time soon. Hopefully, by the end of the year Levin will have some good news to report for 2013's outlook until then this stock is dead.